PolyPid reports Q2 EPS (78c), consensus (55c)

“The second quarter of 2025 was transformational for PolyPid (PYPD) with the successful completion of our SHIELD II Phase 3 trial, which demonstrated significant clinical benefits of D-PLEX in preventing SSIs in abdominal colorectal surgeries,” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “The positive data has generated substantial interest from potential commercial partners and reinforced our conviction in D-PLEX’s potential to address a significant unmet medical need. Moreover, we are extremely encouraged by the enthusiastic reception from healthcare professionals who recognize the potential of D-PLEX to substantially reduce the burden of SSIs, improve patient outcomes, and generate meaningful healthcare cost savings,” continued Ms. Czaczkes Akselbrad. “With our strengthened balance sheet and multiple strategic options before us, we are well-positioned to maximize the value of our innovative technology.”